(S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide

• CAS: 1420477-60-6
• Catalog Number: ACM1420477606
• Category: Pyrazines
• Molecular Weight: 465.5
• Molecular Formula: C26H23N7O2
• Appearance: White Powder

Custom Q&A

What is the molecular formula of acalabrutinib?

The molecular formula of acalabrutinib is C26H23N7O2.

What is the molecular weight of acalabrutinib?

The molecular weight of acalabrutinib is 465.5 g/mol.

When was acalabrutinib created and modified?

Acalabrutinib was created on March 21, 2013, and last modified on December 30, 2023.

What is the approved use for acalabrutinib by the FDA?

Acalabrutinib is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

What is the class of compounds to which acalabrutinib belongs?

Acalabrutinib is a member of the class of imidazopyrazines.

What is the mechanism of action of acalabrutinib?

The mechanism of action of acalabrutinib is as a Tyrosine Kinase Inhibitor.

What other conditions has acalabrutinib been studied for?

Acalabrutinib has been studied for the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma.

Has a new tablet formulation of acalabrutinib been approved?

Yes, a new tablet formulation of acalabrutinib has been approved by the FDA, enabling co-administration with proton pump inhibitors (PPIs).

What designation has acalabrutinib received from the FDA?

Acalabrutinib has received Priority Review, Breakthrough Therapy, and Orphan Drug designations from the FDA.

How many clinical trials have been conducted with acalabrutinib?

More than 35 clinical trials across 40 countries with more than 2500 patients have been conducted with acalabrutinib.